Sarah Carmody | IR and Corporate Communications |
Anna Protopapas | CEO |
Tim Lowinger | Chief Scientific Officer |
Dave Spellman | CFO |
Eva Jack | Chief Business Officer |
Dirk Huebner | CMO |
Jonathan Chang | SVB Leerink |
Jessica Fye | JPMorgan |
Good morning and welcome to the Mersana Therapeutics’ First Quarter 2019 Conference Call. Currently, all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed.